These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29221778)

  • 1. Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor.
    Dinkins ML; Lallemand P; Clemens S
    Sleep Med; 2017 Dec; 40():47-52. PubMed ID: 29221778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D3 Receptors and Restless Legs Syndrome.
    Clemens S
    Curr Top Behav Neurosci; 2023; 60():229-249. PubMed ID: 35435646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
    Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
    Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
    Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
    Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D3 receptor agonist efficacy in restless legs syndrome.
    Casoni F; Galbiati A; Ferini-Strambi L
    Adv Pharmacol; 2019; 84():21-35. PubMed ID: 31229173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D3 and D1 receptors: The Yin and Yang in the treatment of restless legs syndrome with dopaminergics.
    Clemens S; Ghorayeb I
    Adv Pharmacol; 2019; 84():79-100. PubMed ID: 31229178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D1 and D3 receptor modulators restore morphine analgesia and prevent opioid preference in a model of neuropathic pain.
    Rodgers HM; Yow J; Evans E; Clemens S; Brewer KL
    Neuroscience; 2019 May; 406():376-388. PubMed ID: 30910641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
    Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
    Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
    Geyer J; Bogan R
    Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
    Maestri M; Fulda S; Ferini-Strambi L; Zucconi M; Marelli S; Staedler C; Bassetti CL; Manconi M
    Sleep Med; 2014 May; 15(5):570-5. PubMed ID: 24767724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.
    Earley CJ; Uhl GR; Clemens S; Ferré S
    Sleep Med; 2017 Mar; 31():71-77. PubMed ID: 27539027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
    Sixel-Döring F; Trenkwalder C
    Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
    Ferini-Strambi L; Marelli S; Galbiati A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
    Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
    Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome.
    Manconi M; Ferri R; Zucconi M; Clemens S; Giarolli L; Bottasini V; Ferini-Strambi L
    Neurology; 2011 Jul; 77(2):110-7. PubMed ID: 21715702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D
    Rodgers HM; Lim SA; Yow J; Dinkins ML; Patton R; Clemens S; Brewer KL
    Pharmacol Biochem Behav; 2020 Jul; 194():172935. PubMed ID: 32335101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.